MorphoSys' Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study Seite 1

11.12.2023 - MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced comprehensive results from the Phase 3 MANIFEST-2 study investigating pelabresib, an investigational BET inhibitor, in combination with the JAK inhibitor ruxolitinib in JAK inhibitor-naïve ... Seite 1

Related Keywords

,Raajitk Rampal ,Myeloproliferative Neoplasms Program ,Memorial Sloan Kettering Cancer Center ,Hematologic Malignancies ,Memorial Sloan ,Kettering Cancer ,Morphosys Aktie ,